Granted accelerated approval. Additional studies are needed to establish clinical benefit.

POLIVY overview icon

POLIVY+BR was studied in the first and only pivotal, randomized trial to include patients with R/R DLBCL

Learn how POLIVY was studied >

POLIVY efficacy icon

Efficacy data in R/R DLBCL

Discover the efficacy of POLIVY >

POLIVY safety data icon

Safety data for POLIVY+BR vs BR

See the safety data for POLIVY >

POLIVY dosing schedule icon

POLIVY+BR is a fixed course of treatment administered every 21 days for 6 cycles

Understand POLIVY dosing and administration >

POLIVY financial support icon

Committed to helping patients who have been prescribed POLIVY*

Discover financial support options >

*Patients must meet eligibility criteria.

Polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) is included in the NCCN Guidelines® as a preferred treatment option (Category 2A) based on the randomized, controlled GO29365 trial 1,2 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) as a preferred treatment option, after at least 2 prior therapies, for patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for transplant (Category 2A). 2† 

The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 27, 2020. To view the most recent and complete version of the guideline, go to